Ipsen SA

Ipsen SA has secured regulatory approval in Japan for its rare disease treatment Bylvay, expanding its commercial footprint in a market underserved for progressive familial intrahepatic cholestasis (PFIC) and related cholestatic disorders.

Ipsen SA has reported strong financial results for the first half of 2025, with a 9.8% increase in sales and a raised annual sales outlook.

Ipsen Pharmaceuticals has released its half-year statement for 2025, providing key financial metrics and valuation insights.

Ipsen SA, a French pharmaceutical company, has seen its stock price surge to levels above its 52-week high, driven by strategic share buybacks and a stable financial situation.

Ipsen SA has strengthened its leadership team and pipeline with the appointment of a new Executive Vice President and promising data on its drug IQIRVO, positioning the company for sustained growth and success.

Ipsen SA reported a 11.6% sales growth in Q1 2025, driven by strong performance across all therapeutic areas and contributions from products Iqirvo and Bylvay.